{"disease":{"id":"refractory-solid-cancer-patients-unexposed-to-immunotherapy","name":"refractory solid cancer patients unexposed to immunotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07300891","title":"T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Samsung Medical Center","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}